Sweden's RaySearch Q4 sales rise 16%, EBIT up 25%

RaySearch Laboratories AB (publ)

12/02/2026 06:39

Overview

Swedish medical tech firm's Q4 revenue rose 16% yr/yr with 28% organic growth

Q4 operating profit increased by 25% to SEK 92 mln

Company expanded RayStation use in multiple cancer centers

Outlook

RaySearch targets operating margin of at least 25% for full year 2026

Company introduces new strategic function to strengthen market focus

RaySearch sees strong demand across all regions despite geopolitical uncertainty

Result Drivers

RAYSTATION EXPANSION - Expansion of RayStation in multiple cancer centers contributed to Q4 growth

LICENSE SALES - Growing license sales and recurring support revenues provided revenue stability

CURRENCY IMPACT - Strengthened Swedish krona significantly impacted reported net sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 375 mln
Q4 Adjusted EPS
SEK 2
Q4 Net Income
SEK 69 mln
Q4 Operating Profit
SEK 92 mln
Q4 Order Backlog
SEK 1.53 bln
Q4 Orders
SEK 330 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for RaySearch Laboratories AB (publ) is SEK330.00, about 88.1% above its February 11 closing price of SEK175.40

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release: ID:nMFN4TgQ8t

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)